Cytokinetics’ CEO Robert Blum discusses today’s SEQUOIA-HCM P3 result

Octant Bio's Co-Founder & CEO describes technology advances helping to navigate the biological complexity of multi-modal diseases

Fauna Bio signs collaboration with Lilly to leverage understandings from hibernation to discover novel obesity targets

Leveraging enzymes to help scale RNA therapies and other biocatalyst use cases with the CEO of Codexis

The co-founders of 10x Genomics discuss the present and future of cellular and genomic analysis

Playground Global's $410 million new fund and the firm's philosophy of investing in life sciences

Using a covalent menin inhibitor as an approach against diabetes (and more) with Biomea Fusion's CEO

Apple Tree Partners funds a $52M Series A for Deep Apple to leverage virtual screening

Analyst Thursdays: Evercore ISI Analyst Liisa Bayko takes a deep dive into Vertex's pain data

The present and future of gene editing with Fyodor Urnov

Loyal founder Celine Halioua on the science of trying to help dogs live longer

Recapping #ASH23 with Syndax CEO Michael Metzger

Pyruvate kinase activation as a sickle cell disease strategy with Agios' CEO at #ASH23

Gracell's founder explains his company's rationale for BCMA + CD19 in both myeloma and lupus

Talking BTK degraders with the CEO of Nurix Therapeutics at #ASH23

Kicking off Monday (Day 3) of the ASH Annual Meeting with ApexOnco's Jacob Plieth

Mass General's Marcela Maus talks about the latest in cell therapy at #ASH23

Poseida's soon-to-be CEO on this morning's allo BCMA CAR-T data at #ASH23

Vertex COO Stuart Arbuckle on the approval and launch of CASGEVY for sickle cell disease at #ASH23

Incyte CEO Hervé Hoppenot on axatilimab for GvHD, BET inhibition, oral PD-1s and more from #ASH23